Skip to content
Thursday, November 12, 2026
Nova Gaming Market

Users Discontinuing Anti-Obesity Medications Regain Weight Far More Rapidly Compared to People Using Diet and Exercise

Image of pharmaceutical injection and weighing machine
Obesity treatment involves ongoing approaches.

Fresh analysis suggests that people who discontinue new GLP-1 drugs like Wegovy and Mounjaro may regain shed pounds much more quickly than those who end conventional diet and exercise regimens.

Research printed in a leading health publication shows that while overweight people frequently drop substantial amounts of their body weight while on the medication, the weight returns at an estimated rate of 0.8 kg per month once they quit.

"Individuals buying these drugs need to be aware of the risk of quick weight regain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.

This pace of regain means a reversion to starting mass within about a year and a half.

Comparing Treatments

The analysis, which examined dozens of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with other pills.

The team point out that individuals who shed pounds through lifestyle changes alone typically see a more gradual creep back—perhaps 0.1 kg a month—post-intervention.

Understanding the Quick Regain

Nutrition scientists believe the way of the jabs accounts for the heightened regain.

The injections imitate a body's own chemical called glucagon-like peptide-1, which controls hunger.

"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its own natural hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.

"Discontinuation of this hormone supplement means appetite is no longer kept in check, making overeating a significant risk."

A Chronic Condition?

The NHS advise the jabs for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.

Many experts argue that, due to the likelihood of weight regain, the therapy is often ongoing.

This perspective is echoed by pharmaceutical companies, who note that the findings "underscore the chronic character of excess weight," comparing it to managing diseases like hypertension.

User Accounts

Individuals who have stopped the jabs explain a sudden resurgence of hunger.

"I experienced a switch that goes on and you become extremely hungry," said a patient.

This difficulty is compounded if users have not adopted sustainable dietary or behavioural changes during therapy.

Widespread Use

Recent estimates suggest that millions of adults in the UK have used these injections in the past year, with demand continuing to grow.

  • Adoption is greater among women compared to males.
  • The middle-aged demographic shows the greatest usage rates.
  • Many obtain the medications through private prescriptions rather than public health services.

Ultimately, experts caution that while GLP-1 drugs are potent tools for weight loss, they are not a permanent solution and long-term success likely depends on combined lifestyle changes.

JB
Written by

Joshua Barnes

A passionate gaming journalist with over a decade of experience covering esports and tech innovations.

Nova Gaming Market

Type to search articles.